Trial intelligence / Profile preview

TAWIS - Evaluation of Infliximab Withdrawal in Sarcoidosis

2024-516965-35-00Phase 3Authorised

Sponsor: Assistance publique - Hôpitaux de Paris
Start: Oct 2024
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 3, randomised trial of infliximab in sarcoidosis (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Major relapse rate. Planned start Oct 2024; status: authorised.

Drugs

infliximab

Conditions

sarcoidosis

Beyond the preview

Go deeper on 2024-516965-35-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-516965-35-00.